Albuterol treatment efficacy in RSV infection
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Efficacy in RSV Infection: Clinical Outcomes and Patient Response
Limited Effectiveness of Albuterol in RSV Bronchiolitis
Multiple studies have found that albuterol, a commonly used bronchodilator, has limited benefit in infants with RSV-induced bronchiolitis. In a controlled study of infants with severe RSV infection requiring mechanical ventilation, only about 45% of those with obstructive small airway disease showed small but significant improvements in lung function after albuterol treatment, while 50% did not benefit at all, and one patient’s lung function worsened. The study concluded that inhaled albuterol is of limited value and should be discontinued if no clear benefit is observed . Similarly, a double-blind, placebo-controlled trial found that albuterol, whether given orally or by nebulizer, did not improve respiratory rate, symptom scores, oxygen saturation, or hospital admission rates in infants with RSV bronchiolitis compared to placebo .
Potential for Harm and Increased Resource Use
Retrospective analysis of young infants hospitalized with RSV bronchiolitis showed that those who received albuterol often required more time on supplemental oxygen and had longer hospital stays, with statistical significance in some severity groups. This suggests that albuterol may not only be ineffective but could potentially increase the need for supportive care in some cases .
Patient Subgroups and Individualized Treatment
Recent reviews highlight that the response to albuterol in viral bronchiolitis, including RSV, is highly variable. Certain subgroups—such as older infants with rhinovirus bronchiolitis, those with a family history of asthma, or those with specific RSV genotypes—may be more likely to benefit from albuterol. However, for the majority of infants with classic RSV bronchiolitis, routine use of albuterol is not supported by current evidence. Instead, a therapeutic trial may be considered in select cases with specific clinical features, but broad use is not recommended .
Mechanistic Insights: Anti-Inflammatory Effects in Animal Models
Animal studies suggest that the (R)-enantiomer of albuterol may have a stronger anti-inflammatory effect in RSV-infected airways compared to the racemic mixture or the (S)-enantiomer. However, these findings are preclinical and have not yet translated into clear clinical benefits for infants with RSV bronchiolitis .
Comparison with Other Viral Infections
The pattern of albuterol use in other viral lower respiratory tract infections, such as human metapneumovirus (HMPV), mirrors that seen in RSV. Despite frequent use, there is no evidence that albuterol improves outcomes like hospital length of stay in these patients, further questioning its routine use in viral bronchiolitis .
Conclusion
Current research consistently shows that albuterol provides little to no benefit for most infants with RSV bronchiolitis and may even increase the need for supplemental oxygen or prolong hospitalization in some cases. While certain subgroups may respond better, routine use is not supported, and albuterol should be discontinued if no clear improvement is observed. Future research may clarify which patients, if any, could benefit from targeted bronchodilator therapy.
Sources and full results
Most relevant research papers on this topic